Kazia Therapeutics Surges to 198th in Daily Rankings with 4.94 Billion Turnover

On June 11, 2025, Kazia Therapeutics (KZIA) experienced a significant surge in trading volume, with a turnover of 4.94 billion, marking a 718606.12% increase from the previous day. This substantial rise in trading activity placed Kazia at the 198th position in the daily stock market rankings. The company's stock price soared by 81.53%, reflecting a strong market response to recent developments.

Kazia Therapeutics has unveiled promising preclinical research demonstrating the potential of its lead drug, paxalisib, in treating triple-negative breast cancer (TNBC). The study, conducted at QIMR Berghofer Medical Research Institute, showed that paxalisib can reprogram the tumor microenvironment and enhance immune response when combined with immunotherapy. The drug's dual targeting of PI3K and mTOR inhibits cancer cell growth and increases T cell infiltration, leading to synergistic antitumor activity when combined with KEYTRUDA, resulting in tumor regression in preclinical models.

The company has already initiated a Phase 1b clinical trial testing paxalisib in combination with checkpoint inhibitors and chemotherapy for advanced breast cancer, with the first patient dosed. This trial is a critical milestone for validating the preclinical findings and advancing the treatment of TNBC. The extension of paxalisib development into TNBC represents a strategic portfolio expansion, targeting an indication with significant unmet need in the $53 billion immunotherapy market.